Bionano Genomics (DB:2Y30) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

2Y30 Panoramica delle azioni

Provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.

Informazioni sull'azienda

2Y30 analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Revenue is forecast to grow 32.36% per year

Trading at good value compared to peers and industry

Analisi del rischio

Shares are highly illiquid

Does not have a meaningful market cap (€52M)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Bionano Genomics, Inc. Concorrenti

Evotec

XTRA:EVT

€1.1b

MPH Health Care

DB:93M1

€105.3m

Gerresheimer

XTRA:GXI

€3.4b

2invest

XTRA:2INV

€60.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bionano Genomics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$4.39
Massimo di 52 settimane	US$28.00
Minimo di 52 settimane	US$4.39
Beta	2.19
1Variazione di 1 mese	0%
Variazione a 3 mesi	-16.62%
Variazione di 1 anno	-80.92%
3Variazione a 3 anni	13.70%
Variazione a 5 anni	-93.07%
Variazione dall'IPO	-93.25%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2Y30	DE Life Sciences	DE Mercato
7D	0%	-0.2%	1.5%
1Y	-80.9%	3.5%	12.6%

Ritorno vs Industria: 2Y30 underperformed the German Life Sciences industry which returned -22.5% over the past year.

Rendimento vs Mercato: 2Y30 underperformed the German Market which returned 5.9% over the past year.

Volatilità dei prezzi

Is 2Y30's price volatile compared to industry and market?
2Y30 volatility
2Y30 Average Weekly Movement	n/a
Life Sciences Industry Average Movement	6.0%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 2Y30's share price has been volatile over the past 3 months.

Volatilità nel tempo: Insufficient data to determine 2Y30's volatility change over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2003	405	Robert Holmlin	www.bionano.com

Bionano Genomics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bionano Genomics con la sua capitalizzazione di mercato?
2Y30 statistiche fondamentali
Capitalizzazione di mercato	€49.26m
Guadagni(TTM)	-€138.65m
Ricavi(TTM)	€29.82m

1.6x

Rapporto P/S

-0.3x

Rapporto P/E

2Y30 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2Y30 Conto economico (TTM)
Ricavi	US$31.51m
Costo del fatturato	US$23.52m
Profitto lordo	US$7.99m
Altre spese	US$154.51m
Guadagni	-US$146.52m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-3.88
Margine lordo	25.35%
Margine di profitto netto	-464.96%
Rapporto debito/patrimonio netto	0%

Come si è comportato 2Y30 nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

2Y30 Panoramica delle azioni

Premi

Analisi del rischio

Bionano Genomics, Inc. Concorrenti

XTRA:EVT

€1.1b

DB:93M1

€105.3m

XTRA:GXI

€3.4b

XTRA:2INV

€60.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Bionano Genomics, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Bionano Genomics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Bionano Genomics, Inc. Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

Bionano Genomics Receives Non-Compliance Letter from the Nasdaq Stock Market

Bionano Genomics, Inc. has completed a Follow-on Equity Offering in the amount of $9.994188 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000001 million.

Recent updates

Bionano Genomics, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Bionano Genomics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Bionano Genomics, Inc. Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

Bionano Genomics Receives Non-Compliance Letter from the Nasdaq Stock Market

Bionano Genomics, Inc. has completed a Follow-on Equity Offering in the amount of $9.994188 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000001 million.

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Bionano Genomics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.24 loss per share (vs US$1.13 loss in 2Q 2022)

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.10 loss in 1Q 2022)

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.26 loss in FY 2021)

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Bionano Genomics Announces First Publication Using Ogm for Detection of Repeat Expansions in Canvas and Adult-Onset Ataxia

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.067 loss in 2Q 2021)

Bionano Genomics, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Bionano Genomics, Inc. Announces Publication of Research Study in Myelodysplastic Syndrome

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Chromosome Instability During Culture of Induced Pluripotent Stem Cells